Cortagen

Cortagen is a synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology in Russia. It belongs to the Khavinson peptide family of short bioregulatory peptides designed to target specific organ systems. Cortagen acts as a bioregulator of the central nervous system, with research suggesting it supports neuronal function, brain tissue repair, and cognitive processes. Like other Khavinson peptides, it is theorized to work through gene expression modulation rather than traditional receptor-ligand pharmacology.

Mechanism of Action

Cortagen is proposed to interact directly with DNA through sequence-specific binding to gene promoter regions in brain and CNS tissues. According to the Khavinson bioregulation theory, short peptides (2-4 amino acids) can penetrate cell membranes and the nuclear envelope, binding to complementary DNA sequences in the major groove of the double helix. This epigenetic mechanism is thought to regulate the expression of genes involved in neuronal differentiation, neuroprotection, and synaptic plasticity.

Research suggests Cortagen modulates expression of genes related to neurotrophin signaling (including BDNF and NGF pathways), antioxidant defense in neural tissue, and anti-apoptotic pathways that protect neurons from programmed cell death. The peptide has been studied for its ability to normalize cerebral cortex function after ischemic or toxic damage, suggesting a role in neurorestorative processes. As a bioregulator, Cortagen is theorized to restore gene expression patterns toward a more youthful baseline rather than forcing a specific pharmacologic effect.

Research Evidence

Khavinson et al. (2003): demonstrated that Cortagen peptide regulated gene expression in brain tissue cultures and improved recovery of neuronal function following experimental cerebral ischemia in animal models. Khavinson and Malinin (2005): showed short peptides including Cortagen sequence interact with specific DNA regions, supporting the proposed epigenetic mechanism of action.

Khavinson et al. (2014, Bulletin of Experimental Biology and Medicine): reported that Cortagen restored cognitive function and normalized EEG patterns in aged rats, with effects comparable to younger control animals. Studies from the St. Petersburg Institute have also documented Cortagen’s neuroprotective effects against oxidative stress-induced neuronal damage in cell culture models.

Clinical Applications

In Russian clinical practice, Cortagen has been used to support recovery from stroke and traumatic brain injury, age-related cognitive decline, neurodegenerative conditions, and general CNS bioregulation in aging populations. Russian physicians have reported improvements in cognitive function, memory, and neurological recovery when Cortagen is incorporated into treatment protocols. In the international peptide research community, Cortagen is of interest for its potential neuroprotective and neuroregenerative properties, particularly as a low-molecular-weight peptide with reported ability to cross the blood-brain barrier.